Pharma digital marketing has fundamentally changed the speed at which commercial teams are expected to operate. Social posts respond to news cycles. Email campaigns require same-week turnaround. Websites need rapid updates when product information changes. Paid digital content runs across multiple platforms simultaneously.
But the Medical, Legal, and Regulatory (MLR) review process that governs this content was not originally built for digital speed. For many life sciences organizations, the same review workflow used to approve a printed sales aid is now being applied to a social media post. The result is predictable: reviews are slow because the process was not designed for digital content, or compliance corners get cut because digital timelines demand it.
Top-performing pharma digital marketing teams have solved this. They have not lowered their compliance standards. They have built review workflows that match the actual risk profile, complexity, and cadence of each content type.
Traditional promotional materials like printed brochures, sales aids, and event materials are relatively static once approved. They move through a single review cycle, receive approval, and are distributed. Revisions typically prompt a formal re-review.
Pharma digital marketing content operates on a different set of rules entirely:
Each of these scenarios introduces compliance risks that a uniform review process is not equipped to handle efficiently. A brochure workflow built around multiple circulations and multi-day reviewer windows creates serious bottlenecks when applied to content that needs to go live within 48 hours.
The performance variation across content types in pharma digital marketing is wider than most teams expect. According to the 2025 State of Promotional Review Benchmarks Report:
A video that takes more than three times as long to approve as a social post cannot go through the same workflow and meet the same business timelines. When teams apply a uniform process across all content types, they are either over-engineering the approval path for fast-moving digital formats or under-engineering it for complex, high-risk materials.
The days required to incorporate feedback reveal another layer. Website content takes an average of 13.2 days to incorporate feedback after review, compared to 4.7 days for social media and 4.1 days for event materials. Website revisions often involve development resources, not just copy changes, and review workflows that do not account for that reality will consistently underestimate timelines.
For pharma digital marketing teams managing email at scale, the 18.8-day average completion time is a number worth sitting with. That either means starting review significantly earlier than you are today or finding specific places in the email workflow where time is being lost unnecessarily.
The teams that consistently outperform their peers on digital content timelines have made deliberate structural changes to how content moves through the MLR process. Here is what that looks like in practice:
Before a social campaign or digital video goes into full production, a brief concept document is reviewed for claims direction, messaging strategy, and regulatory sensitivities. This puts compliance thinking at the stage where changes are inexpensive, not after a finished asset has entered formal review.
Teams using concept reviews report fewer recirculations on final content because the substantive compliance questions have already been resolved before the creative work begins.
High-performing pharma digital marketing teams do not apply a single workflow to every format. They build differentiated review paths based on the actual risk profile and operational requirements of each content type:
The goal is to calibrate review intensity to compliance risk, not to apply maximum scrutiny to everything or minimum scrutiny to anything digital.
A persistent source of delay for pharma digital marketing teams is the disconnection between review systems and the platforms where digital content lives after approval. When feedback sits in email chains rather than the review record, when approved content is hard to locate downstream, or when assets have to be manually uploaded into a separate system after approval, operational friction adds days to every cycle.
Purpose-built promotional review systems that integrate with your existing technology stack, whether that is a digital asset management platform, a sales enablement tool, a content management system, or another downstream channel, eliminate much of this friction. Approved content moves automatically to where it needs to go. Approval records travel with the asset. Marketing teams can access compliant materials without hunting across multiple systems.
For pharma digital marketing teams operating across multiple markets, digital content introduces additional complexity. The same product claim may require different language, different supporting references, or different disclosures depending on the regulatory environment of each market.
Top-performing teams build market-specific review logic directly into their workflows rather than relying on manual routing. This reduces the risk of content approved in one market being distributed incorrectly in another.
If your team is not tracking these MLR metrics, the benchmark data gives you a clear baseline for what good looks like:
The pharma digital marketing teams moving fastest are not cutting compliance corners. They have built a review system designed for digital content from the ground up, with workflows matched to the actual demands of each format, integrated tooling, and the measurement practices to improve continuously.
Ready to see where your digital content review stands? Download the 2025 state of promotional review benchmarks report.